tetano
Editor, Senior Moderator
Pediatr Infect Dis J
. 2021 Mar 9.
doi: 10.1097/INF.0000000000003122. Online ahead of print.
Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181
Lara Danziger-Isakov[SUP] 1 [/SUP], Nadim Khalil, Allison Divanovic, Robert Frenck, Michael Grimley, Ilias Iliopoulos, Rebecca Marsh, Grant Paulsen, Christine L Phillips, Grant Schulert, Paul Spearman, Samantha Blum, Jennifer Hui-Chin Ho
Affiliations
Abstract
We describe the successful treatment of a 10-month-old female with respiratory distress secondary to Coronavirus disease 2019 (COVID-19) with the nebulized investigational drug, DAS181. Therapy was well tolerated, and the patient had minimal side effects. The patient's respiratory distress and positive viral polymerase chain reaction rapidly resolved after initiation of therapy.
. 2021 Mar 9.
doi: 10.1097/INF.0000000000003122. Online ahead of print.
Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181
Lara Danziger-Isakov[SUP] 1 [/SUP], Nadim Khalil, Allison Divanovic, Robert Frenck, Michael Grimley, Ilias Iliopoulos, Rebecca Marsh, Grant Paulsen, Christine L Phillips, Grant Schulert, Paul Spearman, Samantha Blum, Jennifer Hui-Chin Ho
Affiliations
- PMID: 33902077
- DOI: 10.1097/INF.0000000000003122
Abstract
We describe the successful treatment of a 10-month-old female with respiratory distress secondary to Coronavirus disease 2019 (COVID-19) with the nebulized investigational drug, DAS181. Therapy was well tolerated, and the patient had minimal side effects. The patient's respiratory distress and positive viral polymerase chain reaction rapidly resolved after initiation of therapy.